In order to define biomarkers of response the gene expression of BMI1 and MN1 as well as the protein levels of MCL1 and MEK1 were determined in the mononuclear cells isolated from AML patients at diagnosis (Table 3), and correlated to the response to PTC596 combination treatments (Figure 7A–H). This evidence concerns the gene MAP2K1 and acute myeloid leukemia.